Oncodesign Precision Medicine (OPM) announced the presentation of positive Phase 1 clinical trial data for OPM-101, a first-in-class, orally available RIPK2 inhibitor, at the United European Gastroenterology (UEG) Week congress in Vienna, Austria. The data, presented by Professor Laurent Peyrin-Biroulet, M.D., PhD, of CHRU of Nancy, highlighted the strong safety profile and high target engagement of OPM-101 in healthy volunteers.
Phase 1 Trial Results
The Phase 1 trial evaluated the safety, pharmacokinetics, and pharmacodynamics of OPM-101 in healthy volunteers. According to Professor Peyrin-Biroulet, the results provide "strong evidence that OPM has the potential to advance the treatment of Chronic Inflammatory Bowel Disease as a daily oral therapy for people living with ulcerative colitis."
OPM-101: A RIPK2 Kinase Inhibitor
OPM-101 is designed as a selective inhibitor of RIPK2 kinase. OPM is advancing OPM-101 for the treatment of chronic immuno-inflammatory digestive diseases. The company plans to initiate Phase Ib/IIa trials by the end of 2024.
About Oncodesign Precision Medicine
Oncodesign Precision Medicine (OPM) specializes in precision medicine for resistant and metastatic cancers. Their pipeline includes OPM-201, licensed to Servier for Parkinson's disease, and OPM-102, a preclinical candidate for oncology. OPM utilizes its Nanocyclix® technology platform to develop small macrocyclic kinase inhibitors.
